Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
The abilities of chemokines in orchestrating cellular migration are utilised by different (patho-)biological networks including malignancies. However, except for CXCR4/CXCL12, little is known about the relation between tumour-related chemokine expression and the development and progression of solid tumours like breast cancer. In this study, microarray analyses revealed the overexpression of chemokine CXCL13 in breast cancer specimens. This finding was confirmed by real-time polymerase chain reaction in a larger set of samples (n = 34) and cell lines, and was validated on the protein level performing Western blot, ELISA, and immunohistochemistry. Levels of CXCR5, the receptor for CXCL13, were low in malignant and healthy breast tissues, and surface expression was not detected in vitro. However, we observed a strong (P = 0.0004) correlation between the expressions of CXCL13 and CXCR5 in breast cancer tissues, indicating a biologically relevant role of CXCR5 in vivo. Finally, we detected significantly elevated serum concentrations of CXCL13 in patients with metastatic disease (n = 54) as compared with controls (n = 44) and disease-free patients (n = 48). In conclusion, CXCL13 is overexpressed within breast cancer tissues, and increased serum levels of this cytokine can be found in breast cancer patients with metastatic disease pointing to a role of CXCL13 in the progression of breast cancer, suggesting that CXCL13 might serve as a useful therapeutic target and/or diagnostic marker in this malignancy.
Panse
J
J
Department of Oncology/Hematology, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Friedrichs
K
K
Marx
A
A
Hildebrandt
Y
Y
Luetkens
T
T
Barrels
K
K
Horn
C
C
Stahl
T
T
Cao
Y
Y
Milde-Langosch
K
K
Niendorf
A
A
Kröger
N
N
Wenzel
S
S
Leuwer
R
R
Bokemeyer
C
C
Hegewisch-Becker
S
S
Atanackovic
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000097:blood* / Q000235:genetics* / Q000556:secondary; D045744:Cell Line, Tumor; D054382:Chemokine CXCL13 / Q000097:blood* / Q000235:genetics*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D054380:Receptors, CXCR5 / Q000097:blood / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
C110663:CXCL13 protein, human; C095085:CXCR5 protein, human; D054382:Chemokine CXCL13; D012333:RNA, Messenger; D054380:Receptors, CXCR5
Blood. 2007 Nov 1;110(9):3316-25
17652619
Oncogene. 2005 Jan 20;24(4):573-84
15580304
Eur J Immunol. 2001 May;31(5):1544-9
11465112
Arthritis Rheum. 2005 Jun;52(6):1773-84
15934082
Nat Immunol. 2004 Sep;5(9):943-52
15300245
Br J Haematol. 2006 Feb;132(3):255-67
16409290
Nat Rev Cancer. 2004 Jul;4(7):540-50
15229479
N Engl J Med. 1998 Feb 12;338(7):436-45
9459648
Leuk Lymphoma. 2006 Oct;47(10):2163-73
17071491
Kidney Int. 2005 Apr;67(4):1616-21
15780119
Int J Cancer. 2006 May 1;118(9):2147-57
16331601
Cancer Res. 2005 Jul 15;65(14):6178-88
16024619
J Exp Med. 2004 Jan 5;199(1):59-68
14707115
Cancer Res. 2002 Oct 15;62(20):5930-8
12384559
J Interferon Cytokine Res. 2002 Oct;22(10):1067-8
12433287
Oncogene. 2007 Jun 7;26(27):3998-4008
17213808
J Immunol. 2006 Nov 15;177(10):6713-22
17082584
Clin Cancer Res. 2005 Jun 1;11(11):4117-27
15930347
Blood. 1999 Apr 15;93(8):2463-70
10194423
Int J Hematol. 2000 Dec;72(4):408-11
11197205
Int J Cancer. 2005 Sep 20;116(5):726-33
15828050
J Exp Med. 2000 Apr 17;191(8):1303-18
10770798
Nature. 1998 Feb 19;391(6669):799-803
9486651
Cancer Res. 2006 Oct 1;66(19):9576-82
17018614
Clin Exp Immunol. 2002 Dec;130(3):548-56
12452848
Oncogene. 2005 May 26;24(23):3774-85
15782123
Blood. 2007 Apr 1;109(7):2708-17
17119115
Oncogene. 2003 Nov 6;22(50):8093-101
14603250
Leukemia. 2002 Apr;16(4):650-7
11960346
Int J Cancer. 2006 Apr 15;118(8):2092-7
16287062
Nature. 2001 Mar 1;410(6824):50-6
11242036
Blood. 2004 Nov 15;104(10):3021-7
15284119
Blood. 2001 Mar 15;97(6):1543-8
11238088
Int J Cancer. 2005 Dec 10;117(5):861-5
15981210
J Biol Chem. 2002 Dec 20;277(51):49481-7
12388552